Sfoglia per Autore
Letrozole Versus Letrozole Plus Lapatinib (GW572016) in Hormone-Sensitive, HER2-Negative Operable Breast Cancer: A Double-Blind, Randomized Phase II Study with Biomarker Evaluation (EGF109077-LAP107692/LETLOB)
2008 Frassoldati, A; Guarneri, Valentina; Piacentini, Federico; Jovic, Gordana; Giovannelli, Simona; Oliva, C; Conte, Pierfranco
Frequency and Risk Factors Associated With Osteonecrosis of the Jaw in Cancer Patients Treated With Intravenous Bisphosphonates
2008 Hoff, Ao; Toth, B; Altundag, K; Johnson, M; Warneke, C; Nooka, A; Sayegh, G; Guarneri, Valentina; Desrouleaux, K; Cui, J; Adamus, A; GAGEL RF AND HORTOBAGYI, Gn
Progress in the treatment of Early and Advanced Breast Cancer
2008 Guarneri, Valentina; Piacentini, Federico; Conte, Pierfranco
Magnetic resonance imaging and ultrasonography in predicting pathologic extent after preoperative chemotherapy in stage II-III breast cancer
2008 Guarneri, Valentina; Pecchi, Annarita; Torricelli, Pietro; Piacentini, Federico; A., Frassoldati; C., Mauri; R., Battista; B., Canossi; D'Amico, Roberto; Conte, Pierfranco
PREDICTIVE AND PROGNOSTIC ROLE OF P53 EXPRESSION IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY: A SINGLE INSTITUTION ANALYSIS
2009 Guarneri, V.; Piacentini, F.; Barbieri, E.; Ficarra, G.; Conte, Pf.
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVE: ANALISI PRELIMINARE DELLE TOSSICITA’
2009 Ferrari, A.; Grisolia, D.; Piacentini, F.; Barbieri, E.; Guarneri, V.; Frassoldati, A.; Giovannelli, S.; Sabbatini, R.; Pagano, M.; Vicini, R.; Conte, Pf.
Acute and subacute toxicities of medical anticancer treatment. ESMO handbook of cancer diagnosis and treatment evaluation, pag 79-99 . Informa Healthcare USA, 2009, ISBN 978-1-841-84703-0
2009 Guarneri, Valentina; Conte, Pierfranco
ShortHER: TRATTAMENTO ADIUVANTE CON HERCEPTIN PER 3 MESI VERSO 12 MESI, IN ASSOCIAZIONE CON DUE DIFFERENTI REGIMI DI CHEMIOTERAPIA, NELLE PAZIENTI CON CARCINOMA MAMMARIO HER2 POSITIVO
2009 Piacentini, F.; Ferrari, A.; Barbieri, E.; Guarneri, V.; Frassoldati, A.; Giovannelli, S.; Sabbatini, R.; Pagano, M.; Grisolia, D.; Vicini, R.; Conte, Pf
Analysis of Bevacizumab (Bev) Therapy, Bisphosphonate Use and Osteonecrosis of the Jaw (ONJ) in >1900 Patients Treated in Two Randomized, Controlled Trials
2009 Guarneri, Valentina; Miles, D; Robert, Nj; Dieras, Vc; Glaspy, J; Smith, Ie; Thomssen, C; Biganzoli, L; Taran, T; Conte, Pierfranco
Preplanned first-step analysis of LET-LOB neoadjuvant study: A double-blind randomized phase IIb trial of letrozole (L) plus lapatinib (Lp) or placebo (P) in postmenopausal HER2-ve, HR+ve operable breast cancer.
2009 A., Frassoldati; Guarneri, Valentina; A., Bottini; K., Cagossi; L., Cavanna; G., Bisagni; D'Amico, Roberto; Piacentini, Federico; C., Oliva; Conte, Pierfranco
Metastatic breast cancer: Therapeutic options according to molecular subtypes and prior adjuvant therapy
2009 Guarneri, Valentina; Conte, Pierfranco
Triple-negative breast cancer: current management and future options.
2009 Conte, Pierfranco; Guarneri, Valentina
P53 EXPRESSION IS A SIGNIFICANT PREDICTOR OF RESPONSE AND PROGNOSIS IN STAGE II-III BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY
2009 Guarneri, V.; Piacentini, F.; Barbieri, E.; Frassoldati, A.; Ficarra, G.; D’Amico, R.; Conte, Pf.
Anthracycline-based preoperative chemotherapy plus lapatinib and trastuzumab or both in HER2-positive breast cancer: Preliminary cardiac safety report of the CHER LOB trial.
2009 Guarneri, Valentina; A., Frassoldati; A., Bottini; K., Cagossi; L., Cavanna; A., Ravaioli; D., Amadori; G., Giardina; C., Oliva; Conte, Pierfranco
Lapatinib plus letrozole for postmenopausal patients with advanced HER2+/HR+ breast cancer
2009 Guarneri, Valentina
The clinical relevance of endocrine therapy induced changes in lipid metabolism in breast cancer patients
2009 Frassoldati, A; Guarneri, Valentina; Conte, Pierfranco
A prognostic model based on nodal status and Ki-67 predicts the risk of recurrence and death in breast cancer patients with residual disease after preoperative chemotherapy.
2009 Guarneri, Valentina; Piacentini, Federico; Ficarra, G; Frassoldati, A; D'Amico, Roberto; Giovannelli, Simona; Maiorana, Antonino; Jovic, Gordana; Conte, Pierfranco
Safety and Activity Report of a Randomized Phase II Trial of Preoperative Anthracycline-Based Chemotherapy Plus Lapatinib, Trastuzumab or Both in HER2 Positive Breast Cancer: CHERLOB Trial.
2009 Guarneri, Valentina; Frassoldati, A; Bottini, A; Cagossi, K; Piacentini, Federico; Ravaioli, A; Cavanna, L; Amadori, D; Bisagni, G; Giardina, G; Conte, Pierfranco
Discordant HER2 Total and HER2 Homodimer Levels by HERmark Analysis in Matched Primary and Metastatic Breast Cancer FFPE Specimens.
2009 Leitzel, K; Conte, Pierfranco; Guarneri, Valentina; Barbieri, Elena; Huang, W; Ali, Sm; Haddad, M; Sperinde, J; Lie, Y; Weidler, J; Bates, M; Lipton, A.
KI67 AS A PREDICTOR OF RESPONSE AND LONG TERM SURVIVAL IN HORMONE RECEPTOR POSITIVE/HER2 NEGATIVE BREAST CANCER PATIENTS TREATED WITH PREOPERATIVE CHEMOTHERAPY
2010 Barbieri, Elena; Piacentini, Federico; Dieci, Maria Vittoria; Ficarra, Guido; Conte, Pierfranco; Guarneri, Valentina
Legenda icone
- file ad accesso aperto
- file disponibili sulla rete interna
- file disponibili agli utenti autorizzati
- file disponibili solo agli amministratori
- file sotto embargo
- nessun file disponibile